Phase I trial of weekly paclitaxel in advanced lung cancer

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 153-158

  Akerley, Wallace ^a   Glantz, Michael ^a   Choy, Hak ^a   Rege, Vishram ^a   Sambandam, Sundaresan ^a   Joseph, Plakyil ^a   Yee, Loren ^a   Rodrigues, Brigid ^a   Wingate, Patti ^a   Leone, Louis ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH;

EID: 0031972610     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.153     Document Type: Article

References (19)

1. SEER Program: Cancer Incidence and Mortality in the United States 1973-1981. NIH Publication No. 85-1837. Bethesda, MD, National Institutes of Health, 1985
2. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data in individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
3. Bonomi P, Kim K, Chang A, et al: Phase II trial comparing etoposide, cisplatin versus Taxol, cisplatin, G-CSF versus Taxol, cisplatin in advanced non small cell lung cancer. An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 15:382, 1996 (abstr 1145)
4. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated non-small cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
5. Chang AY, Kim K, Glick J, et al: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-394, 1993
6. Arbuck S, Canetta R, Onetto O, et al: Current dosage and schedule issues in the development of paclitaxel. Semin Oncol 20:31-39, 1993 (suppl 3)
7. Huizing M, Keung A, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
8. Sarosy G, Kohn E, Stone DA, et al: Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1065-1070, 1992
9. Schiller JH, Storer B, Tutsch K, et al: Phase I trial of 3 hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248, 1994
10. Eisenhauer E, Huinink W, Swenerton K, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
11. Nabholtz J, Gelman K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
12. Parness J, Horwitz SB: Taxol binds to polymerized tubulin in vitro. J Cell Biol 91:479-487, 1981
13. Manfredi JJ, Parness J, Horwitz SB: Taxol binds to cellular microtubules. J Cell Biol 94:688-696, 1982
14. Rose W: Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. Monogr Natl Cancer Inst 15:47-53, 1993
15. Choy H, Akerley W, Safran H, et al: Phase I trial of paclitaxel and thoracic radiation in NSCLC. J Clin Oncol 12:2682-2686, 1994
16. Glantz MJ, Choy H, Kearns CM, et al: Phase I study of weekly outpatient paclitaxel and cranial irradiation in adults with astrocytomas. J Clin Oncol 14:600-609, 1996
17. Golberg HL, Vanice SB: Pneumonitis related to treatment with paclitaxel. J Clin Oncol 13:534-535, 1995
18. Gianni L, Kearns C, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
19. Millward M, Bishop J, Friedlander M, et al: Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 14:142-148, 1996